Key Insights

Highlights

Success Rate

70% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

10.7%

3 terminated out of 28 trials

Success Rate

70.0%

-16.5% vs benchmark

Late-Stage Pipeline

36%

10 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed with results

Key Signals

1 with results70% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (3)
P 1 (1)
P 3 (5)
P 4 (5)

Trial Status

Completed7
Active Not Recruiting6
Unknown6
Recruiting3
Terminated3
Not Yet Recruiting3

Trial Success Rate

70.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (28)

Showing 20 of 20 trials
NCT05404763Active Not Recruiting

Mepolizumab and Physical Activity in Severe Asthma

NCT06488755Phase 3RecruitingPrimary

SIM0718 Treatment of Asthma Clinical Study

NCT05091385CompletedPrimary

Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma

NCT05763121Phase 3Terminated

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

NCT05813288Phase 3Terminated

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

NCT07174713Not ApplicableNot Yet RecruitingPrimary

REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM)

NCT05748600Phase 3Active Not Recruiting

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT03733535Not ApplicableActive Not RecruitingPrimary

Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI

NCT05942222Phase 4Active Not Recruiting

A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT05144087Active Not RecruitingPrimary

The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma

NCT06676397Not ApplicableNot Yet RecruitingPrimary

Homeostatic Roles of Eosinophils in Asthma

NCT05787678UnknownPrimary

Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion

NCT04456270Completed

Asthma Control in a Dutch Primary Care Population

NCT04565483Phase 4RecruitingPrimary

Predictive Signature of Benralizumab Response

NCT06288516Phase 4RecruitingPrimary

BenRalizumab Effect on Airway Remodeling in Severe asTHma

NCT05270278CompletedPrimary

Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy

NCT06270576Phase 1Not Yet RecruitingPrimary

Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma

NCT04612556Active Not RecruitingPrimary

Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)

NCT04710134Phase 4CompletedPrimary

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma

NCT04742504CompletedPrimary

Interaction Between Benralizumab and Basophils in Eosinophilic Asthma

Scroll to load more

Research Network

Activity Timeline